AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25223947 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal Chevron Metatarsal Osteotomy (PCMO)
Number of subjects: 60
Study 25223947 — intervention group
Group type: COMPARATOR
Intervention: Distal Chevron Metatarsal Osteotomy (DCMO)
Number of subjects: 60
Study 23632203 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycaemic index Brazilian diet combined with DASH principles
Number of subjects: 206
Study 23632203 — intervention group
Group type: COMPARATOR
Intervention: Standard care focused on salt intake reduction (Control Group)
Number of subjects: 206
Study 21620395 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OC)
Number of subjects: 0
Study 21620395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19445822 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine alone (150 mg)
Number of subjects: 15
Study 19445822 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine plus a catechin mixture (600 mg) enriched in EGCG
Number of subjects: 15
Study 19445822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 16786231 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab facilitated primary angioplasty (FP)
Number of subjects: 48
Study 16786231 — intervention group
Group type: COMPARATOR
Intervention: On-site fibrin-specific thrombolytic therapy (TT)
Number of subjects: 48
Study 14962331 — intervention group
Group type: EXPERIMENTAL
Intervention: Roc 0.4 mg.kg(‐1)
Number of subjects: 68
Study 14962331 — intervention group
Group type: EXPERIMENTAL
Intervention: Miv 0.133 mg.kg(‐1)
Number of subjects: 68
Study 14962331 — intervention group
Group type: EXPERIMENTAL
Intervention: Roc 0.32 + Miv 0.027 mg.kg(‐1)
Number of subjects: 68
Study 14962331 — intervention group
Group type: EXPERIMENTAL
Intervention: Roc 0.24 + Miv 0.053 mg.kg(‐1)
Number of subjects: 68
Study 14962331 — intervention group
Group type: EXPERIMENTAL
Intervention: Roc 0.16 + Miv 0.08 mg.kg(‐1)
Number of subjects: 68
Study 14962331 — intervention group
Group type: EXPERIMENTAL
Intervention: Roc 0.08 + Miv 0.106 mg.kg(‐1)
Number of subjects: 68
Study 14962331 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination groups (Roc + Miv)
Number of subjects: 68
Study 11098963 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim 300 microg subcutaneously once daily for 7 days
Number of subjects: 59
Study 11098963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 11098963 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim
Number of subjects: 59
Study 9049456 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrolyte-poor water supplementation (2 L/day)
Number of subjects: 11
Study 9049456 — intervention group
Group type: EXPERIMENTAL
Intervention: HCO3-rich water supplementation (2 L/day, 47.5 mmol/L)
Number of subjects: 11
Study 9049456 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control mentioned)
Number of subjects: 11
Study 8075257 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin/sulbactam (3 g every 6 hours)
Number of subjects: 96
Study 8075257 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin (500 mg every 6 hours)
Number of subjects: 96
Study 2587285 — intervention group
Group type: EXPERIMENTAL
Intervention: CVM exercise with a resistance device
Number of subjects: 48
Study 2587285 — intervention group
Group type: EXPERIMENTAL
Intervention: CVM exercise without a device
Number of subjects: 48
Study 2587285 — intervention group
Group type: COMPARATOR
Intervention: No exercise with device in place
Number of subjects: 48
Study 1266792 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet meeting NIH criteria for type II or IV hyperlipoproteinemia
Number of subjects: 0
Study 1266792 — intervention group
Group type: COMPARATOR
Intervention: Diet controlled in fat
Number of subjects: 0
Study 1266792 — intervention group
Group type: EXPERIMENTAL
Intervention: NIH type IV diet
Number of subjects: 0
Study 1266792 — intervention group
Group type: COMPARATOR
Intervention: Diet controlled in fat with caloric restriction
Number of subjects: 0
Study 31181206 — intervention group
Group type: EXPERIMENTAL
Intervention: NI-VATS
Number of subjects: 198
Study 30684398 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message reminders to use selected postabortion contraceptive methods
Number of subjects: 120
Study 30684398 — intervention group
Group type: COMPARATOR
Intervention: No text message reminders
Number of subjects: 120
Study 30684398 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message reminders
Number of subjects: 120
Study 26176074 — intervention group
Group type: EXPERIMENTAL
Intervention: No-touch isolation technique
Number of subjects: 80
Study 26176074 — intervention group
Group type: COMPARATOR
Intervention: Traditional hepatectomy
Number of subjects: 80
Study 21707184 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppress intrusive thought
Number of subjects: 100
Study 21707184 — intervention group
Group type: COMPARATOR
Intervention: Monitor intrusive thought
Number of subjects: 100
Study 20693570 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported answer to a screening question about binge drinking (5 or more standard drinks on one occasion) within the past 90 days
Number of subjects: 354
Study 20693570 — intervention group
Group type: COMPARATOR
Intervention: Self-reported answer to a question about drinking quantity (weekly consumption of 8 or more standard drinks) within the past 90 days
Number of subjects: 354
Study 18831420 — intervention group
Group type: EXPERIMENTAL
Intervention: Akten 1.5%
Number of subjects: 209
Study 18831420 — intervention group
Group type: EXPERIMENTAL
Intervention: Akten 2.5%
Number of subjects: 209
Study 18831420 — intervention group
Group type: EXPERIMENTAL
Intervention: Akten 3.5%
Number of subjects: 209
Study 18831420 — intervention group
Group type: COMPARATOR
Intervention: Sham gel
Number of subjects: 209
Study 16098074 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified treatment arm (idarubicin 42 mg/m2, melphalan 200 mg/m2, cyclophosphamide 120 mg/kg)
Number of subjects: 56
Study 16098074 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment arm (melphalan 200 mg/m2)
Number of subjects: 56
Study 12444815 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 1955
Study 12444815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1955
Study 12444815 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (open-label)
Number of subjects: 1955
Study 10616771 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC1w (omeprazole 20mg bid + amoxicillin 1000mg bid + clarithromycin 400mg bid for 1 week)
Number of subjects: 147
Study 10616771 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC2w (omeprazole 20mg bid + amoxicillin 1000mg bid + clarithromycin 400mg bid for 2 weeks)
Number of subjects: 147
Study 8572853 — intervention group
Group type: COMPARATOR
Intervention: Consultation tailored to needs (C)
Number of subjects: 300
Study 8572853 — intervention group
Group type: EXPERIMENTAL
Intervention: One-hour course about diet (CC)
Number of subjects: 300
Study 8572853 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 300
Study 2695413 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium (550 mg twice daily, from day -7 to the 4th day of the cycle)
Number of subjects: 28
Study 2695413 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for the first three cycles)
Number of subjects: 28
Study 2695413 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium
Number of subjects: 28
Study 321147 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl strophanthanin (0.5 mg initially, followed by 0.25 mg four hours later)
Number of subjects: 59
Study 321147 — intervention group
Group type: COMPARATOR
Intervention: Control group (no acetyl strophanthanin)
Number of subjects: 59
Study 31273965 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Cleaning Device
Number of subjects: 15
Study 31273965 — intervention group
Group type: COMPARATOR
Intervention: Control (artificial tears and lid warming)
Number of subjects: 15
Study 28196066 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education program
Number of subjects: 212
Study 28196066 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (Control)
Number of subjects: 212
Study 25664155 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam 40 mg mixed with normal saline 100 ml (Group N)
Number of subjects: 50
Study 25664155 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Group C)
Number of subjects: 50
Study 23307959 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg PEA, twice a day for three months (T1)
Number of subjects: 40
Study 23307959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23307959 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg PEA, after washout period (T3)
Number of subjects: 40
Study 23307959 — intervention group
Group type: COMPARATOR
Intervention: Placebo, after washout period (T3)
Number of subjects: 40
Study 23307959 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline measurements
Number of subjects: 40
Study 21543960 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training
Number of subjects: 41
Study 21543960 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm ergometry
Number of subjects: 41
Study 21543960 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 41
Study 21543960 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care
Number of subjects: 41
Study 19467544 — intervention group
Group type: EXPERIMENTAL
Intervention: rG‐CSF (10 microg/kg/day) for 3 days
Number of subjects: 200
Study 19467544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 16432054 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine + ramipril
Number of subjects: 17
Study 16432054 — intervention group
Group type: COMPARATOR
Intervention: L-NG-nitro-arginine-methyl-ester (2 mg/kg) during ramipril
Number of subjects: 17
Study 14768658 — intervention group
Group type: EXPERIMENTAL
Intervention: Cafeteria-based intervention including daily activities to increase availability, attractiveness, and encouragement for fruit and vegetable consumption, along with special events over two school years.
Number of subjects: 1668
Study 14768658 — intervention group
Group type: COMPARATOR
Intervention: Control condition (not specified in detail).
Number of subjects: 1668
Study 11765593 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 50 mg Ferring tablets (test preparation)
Number of subjects: 13
Study 11765593 — intervention group
Group type: COMPARATOR
Intervention: Reference preparation (control)
Number of subjects: 13
Study 9239399 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone 400 mg daily for 12 weeks
Number of subjects: 21
Study 9239399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 8393019 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (3 x 4 mg)
Number of subjects: 14
Study 8393019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 3722617 — intervention group
Group type: COMPARATOR
Intervention: Immediate reward completion in hyperactive children
Number of subjects: 32
Study 3722617 — intervention group
Group type: COMPARATOR
Intervention: Short-active delay trial
Number of subjects: 32
Study 30251109 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise programs + hypocaloric diet
Number of subjects: 167
Study 25842202 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 43
Study 25842202 — intervention group
Group type: COMPARATOR
Intervention: Control group (demographically similar, N = 32, scanned twice)
Number of subjects: 43
Study 24515256 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling (LC) plus metformin (target dose of 1,000 mg twice daily)
Number of subjects: 54
Study 24515256 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle counseling (LC) only
Number of subjects: 54
Study 22505373 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate 300 mg q.i.d., esomeprazole 40 mg b.i.d., tetracycline 500 mg q.i.d., and amoxicillin 1 g b.i.d. (bismuth group)
Number of subjects: 200
Study 22505373 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 40 mg b.i.d., tetracycline 500 mg q.i.d., amoxicillin 1 g b.i.d., and metronidazole 500 mg t.i.d. (concomitant group)
Number of subjects: 200
Study 20386337 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported physical activity (PA)
Number of subjects: 2240
Study 20386337 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometer-measured moderate- to vigorous-intensity PA (MVPA)
Number of subjects: 2240
Study 20386337 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometer-measured vigorous-intensity PA (VPA)
Number of subjects: 2240
Study 20386337 — intervention group
Group type: COMPARATOR
Intervention: Diabetes medication usage and history of cardiovascular disease
Number of subjects: 2240
Study 18471061 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation (vitamins A, B complex, C, E, and selenium)
Number of subjects: 887
Study 15598945 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine-Gemcitabine (VG)
Number of subjects: 165
Study 15598945 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin-Paclitaxel (CP)
Number of subjects: 165
Study 12859471 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 ml.kg‐1 Hartmann's solution (supplemental fluid)
Number of subjects: 80
Study 12859471 — intervention group
Group type: COMPARATOR
Intervention: 2 ml.kg‐1 Hartmann's solution (conservative fluid)
Number of subjects: 80
Study 10690832 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous broad-spectrum antibiotic immediately after induction of anesthesia (group 1)
Number of subjects: 265
Study 10690832 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative lavage of the rhinostomy site just after suture of the anterior mucosal flaps (group 2)
Number of subjects: 265
Study 10690832 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative course of oral antibiotics (group 3)
Number of subjects: 265
Study 8645644 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (2.7 g/day n‐3 fatty acids)
Number of subjects: 533
Study 8645644 — intervention group
Group type: COMPARATOR
Intervention: Control (olive oil or no oil supplementation)
Number of subjects: 533
Study 8645644 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 533
Study 1825475 — intervention group
Group type: EXPERIMENTAL
Intervention: CP + SR-2508
Number of subjects: 39
Study 1825475 — intervention group
Group type: COMPARATOR
Intervention: CP alone
Number of subjects: 39
Study 1825475 — intervention group
Group type: EXPERIMENTAL
Intervention: SR-2508
Number of subjects: 39
Study 1825475 — intervention group
Group type: EXPERIMENTAL
Intervention: CP
Number of subjects: 39
Study 6823925 — intervention group
Group type: EXPERIMENTAL
Intervention: Furazolidone for ten days
Number of subjects: 22
Study 6823925 — intervention group
Group type: COMPARATOR
Intervention: Furazolidone for five days
Number of subjects: 22
Study 6823925 — intervention group
Group type: EXPERIMENTAL
Intervention: Furazolidone for ten days (retreatment)
Number of subjects: 22
Study 31881990 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy Activity and Awareness Intervention (PAAI) for 8 weeks
Number of subjects: 146
Study 31881990 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching Recovery Techniques (TRT) for 6 weeks
Number of subjects: 146
Study 31881990 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention group for both PAAI and TRT
Number of subjects: 146
Study 29953304 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 245
Study 29953304 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-Based Mindfulness-Based Cognitive Therapy (eMBCT)
Number of subjects: 245
Study 29953304 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 245
Study 27621609 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (4×100 μg/puff in the UK; 4×90 μg/puff in the US)
Number of subjects: 54
Study 27621609 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium (4×20 μg/puff)
Number of subjects: 54
Study 27621609 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol
Number of subjects: 54
Study 23663079 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedative music played for the first hour in bed
Number of subjects: 24
Study 23663079 — intervention group
Group type: COMPARATOR
Intervention: Control (without music)
Number of subjects: 24
Study 21492253 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine-diluted BTX-A
Number of subjects: 8
Study 21492253 — intervention group
Group type: COMPARATOR
Intervention: Saline-diluted BTX-A
Number of subjects: 8
Study 18925392 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant IL-21 (rIL-21) administered by intravenous bolus injection at dose levels from 1 to 100 microg/kg
Number of subjects: 0
Study 18925392 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 + 9 dosing regimen of rIL-21
Number of subjects: 0
Study 18925392 — intervention group
Group type: EXPERIMENTAL
Intervention: 3/w dosing regimen of rIL-21
Number of subjects: 0
Study 17342356 — intervention group
Group type: EXPERIMENTAL
Intervention: Sternal closure with corpus sterni reinforcement (group 2)
Number of subjects: 71
Study 17342356 — intervention group
Group type: COMPARATOR
Intervention: Standard sternal closure techniques (group 1)
Number of subjects: 71
Study 15378666 — intervention group
Group type: EXPERIMENTAL
Intervention: milnacipran (up to 200 mg/day)
Number of subjects: 125
Study 15378666 — intervention group
Group type: EXPERIMENTAL
Intervention: milnacipran (twice daily)
Number of subjects: 125
Study 15378666 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 125
Study 11556124 — intervention group
Group type: COMPARATOR
Intervention: 10 x 2 mg prednisolone tablets
Number of subjects: 13
Study 11556124 — intervention group
Group type: COMPARATOR
Intervention: 4 x 5 mg prednisolone tablets
Number of subjects: 13
Study 11556124 — intervention group
Group type: COMPARATOR
Intervention: 20 mg prednisolone tablet formulation
Number of subjects: 13
Study 9748025 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan 10 mg
Number of subjects: 473
Study 9748025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 473
Study 7833518 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable clips
Number of subjects: 50
Study 7833518 — intervention group
Group type: COMPARATOR
Intervention: Metal clips
Number of subjects: 50
Study 3416729 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol doses (0.25, 0.5 and 0.75 g/kg of 95% ethanol)
Number of subjects: 4
Study 3416729 — intervention group
Group type: COMPARATOR
Intervention: Control (no alcohol)
Number of subjects: 4
Study 31204824 — intervention group
Group type: EXPERIMENTAL
Intervention: PFI-NAC (1-session personalized feedback intervention)
Number of subjects: 63
Study 31204824 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 63
Study 29900909 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal therapy (scaling and root planning)
Number of subjects: 30
Study 29900909 — intervention group
Group type: COMPARATOR
Intervention: Healthy periodontium (Group I)
Number of subjects: 30
Study 29900909 — intervention group
Group type: COMPARATOR
Intervention: Chronic generalized periodontitis (Group II) before treatment
Number of subjects: 30
Study 27404009 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone raffle intervention (weekly for clients, monthly for peer promoters and providers)
Number of subjects: 7
Study 27404009 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 7
Study 27404009 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone raffle intervention (Iringa region subanalysis)
Number of subjects: 7
Study 27404009 — intervention group
Group type: COMPARATOR
Intervention: Control group (Iringa region subanalysis)
Number of subjects: 7
Study 24096084 — intervention group
Group type: EXPERIMENTAL
Intervention: Purported weight-loss supplement (placebo)
Number of subjects: 0
Study 24096084 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 21443756 — intervention group
Group type: EXPERIMENTAL
Intervention: Cream A [3% PLA-retinyl retinoate (2%) microsphere] applied twice daily
Number of subjects: 44
Study 21443756 — intervention group
Group type: COMPARATOR
Intervention: Cream B (0.06% retinyl retinoate) applied twice daily
Number of subjects: 44
Study 20108154 — intervention group
Group type: EXPERIMENTAL
Intervention: CO(2) insufflation
Number of subjects: 89
Study 20108154 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 89
Study 18753058 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive treatment with directional soft tube placement
Number of subjects: 75
Study 18753058 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (medication)
Number of subjects: 75
Study 15802855 — intervention group
Group type: EXPERIMENTAL
Intervention: Misasa hot spring district residents (exposed to radon)
Number of subjects: 0
Study 15802855 — intervention group
Group type: COMPARATOR
Intervention: Control district residents
Number of subjects: 0
Study 12091260 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 20-40 mg for 8 weeks followed by 16 weeks of fixed dose and then randomisation to citalopram for at least 48 weeks
Number of subjects: 121
Study 12091260 — intervention group
Group type: COMPARATOR
Intervention: Placebo for at least 48 weeks
Number of subjects: 121
Study 12091260 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 121
Study 11185677 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (20 mg/day)
Number of subjects: 10
Study 11185677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8543937 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg/day
Number of subjects: 10
Study 8543937 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline 150 mg/day
Number of subjects: 10
Study 8543937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2037418 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenol treatment on tympanic membrane prior to myringotomy
Number of subjects: 46